Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Toxin A (TcdA) and Toxin B (TcdB) are large clostridial glucosylating toxins produced by *Clostridioides difficile*, a bacterial pathogen responsible for severe antibiotic-associated diarrhea and colitis. Both toxins are AB-type exotoxins, consisting of an enzymatic "A" subunit (N-terminal glucosyltransferase domain) and a "B" subunit (delivery domain with receptor-binding, pore-forming, and autoprotease domains). Upon binding host cell receptors and internalization, the toxins translocate their glucosyltransferase domain into the cytosol, where they inactivate Rho family GTPases by glucosylation, ultimately disrupting the actin cytoskeleton, cell signaling, and leading to cell death. Both TcdA and TcdB are major therapeutic targets for monoclonal antibody-based therapies and are the central diagnostic markers for *C. difficile*-associated disease.
Direct neutralization of toxin by monoclonal antibody (bezlotoxumab blocks TcdB binding to host cells); Inhibition of toxin-induced cell glucosylation; Preventing toxin-receptor interaction and internalization
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Toxin A/B (TcdA; TcdB).